Liliana Seicaru

Dr. Liliana Seicaru


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
A(Andreea Daniela Caloian (Gheorghe)
Andreea Daniela Caloian (Gheorghe)
MCMiruna Cristian
Miruna Cristian
ECElena Calin
Elena Calin
APAndreea Raluca Pricop
Andreea Raluca Pricop
SMStelian Ilie Mociu
Stelian Ilie Mociu
LMLaura Mazilu
Laura Mazilu
DLBCL is a testament to the complexity of nature. It is characterized by remarkable diversity in its molecular and pathological subtypes and clinical manifestations. Despite the strides made in DLBCL treatment and the introduction of innovative drugs, around one-third of patients face a relapse or develop refractory disease. Recent findings over the past ten years have highlighted the critical interplay between the evolution of DLBCL and various epigenetic mechanisms, including chromatin remodeling, DNA methylation, histone modifications, and the regulatory roles of non-coding RNAs. These epigenetic alterations are integral to the pathways of oncogenesis, tumor progression, and the development of therapeutic resistance. In the past decade, the identification of dysregulated epigenetic mechanisms in lymphomas has paved the way for an exciting field of epigenetic therapies. Crucially, these epigenetic transformations span beyond tumor cells to include the sophisticated network within the tumor microenvironment (TME). While the exploration of epigenetic dysregulation in lymphoma cells is thriving, the mechanisms affecting the functions of immune cells in the TME invite further investigation. This review is dedicated to weaving together the narrative of epigenetic alterations impacting both lymphoma cells with a focus on their infiltrating immune companions.

27 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Denisa Gabriela Ion-AndreiDenisa Gabriela Ion-Andrei
Denisa Gabriela Ion-Andrei
AGAlexandra Cristiana Gache
Alexandra Cristiana Gache
EMElena Mocanu
Elena Mocanu
APAndreea Cristina Postu
Andreea Cristina Postu
SLSimona-Alina Lupșă
Simona-Alina Lupșă
EDElena Dantes
Elena Dantes
Background: Accurate prognostic assessment in lung cancer is challenging, especially in settings with limited access to molecular testing. Routine hematological markers may complement TNM staging in identifying high-risk patients. Methods: We retrospectively analyzed 304 patients with histologically confirmed lung cancer to evaluate the prognostic value of hematological and inflammatory markers in relation to tumor stage and ECOG performance status. Survival was estimated using Kaplan–Meier analysis and independent predictors were identified through Cox regression. Cluster analysis integrated hematological markers with tumor characteristics. Results: Most patients presented with advanced disease (61.2% T4; 57.1% metastatic). Early stages (≤IIC) were associated with nearly double the median overall survival compared with stages ≥IIIA (p = 0.001). Nodal involvement and metastases further stratified outcomes. Among hematological markers, anemia (Hb < 11.85 g/dL) and leukocytosis (WBC > 11.71 × 109/L) predicted shorter survival and remained independent predictors in the multivariable Cox model (HR 1.70, p < 0.001; HR 1.54, p = 0.004), along with T4 stage (HR 1.47, p = 0.015). PLT count and fibrinogen were significant in univariate analysis but not after adjustment, while CRP and D-dimer showed no association. Cluster analysis identified two subgroups, with patients in Cluster 2 (T4 stage, anemia, leukocytosis) experiencing more than double the mortality risk compared with Cluster 1 (HR 2.33, p < 0.001). Conclusions: TNM stage remains the dominant prognostic factor in lung cancer. However, Hb and WBC count provide additional prognostic information, and cluster analysis may refine risk stratification by capturing clinically relevant heterogeneity.

28 July 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
COCristian Ionut Orasanu
Cristian Ionut Orasanu
MAMariana Aschie
Mariana Aschie
MDMariana Deacu
Mariana Deacu
Liliana SeicaruLiliana Seicaru
Liliana Seicaru
RVRaluca Ioana Voda
Raluca Ioana Voda
GCGeorgeta Camelia Cozaru
Georgeta Camelia Cozaru
Giant cell glioblastoma is a rare tumor entity of IDH-wildtype glioblastoma. It is usually found in the pediatric population. We describe a particular case of a female patient diagnosed histopathologically with giant cell glioblastoma, who had two recurrences in different lobes of the same cerebral hemisphere, despite positive prognostic factors and appropriate treatment. We performed an immunohistochemical characterization of giant cell glioblastoma as well as an analysis of its aggressiveness using the cytogenetic markers TP53, CDKN2A, and TP73 using the FISH technique. The clinical picture was inconsistant, the suspicion being completely different initially. Paraclinical examination and imaging initially suggested a metastasis to the insular lobe. After surgery, histopathological and immunohistochemical examinations were the basis for the diagnosis. Despite the prognostic factors known so far in the literature, the aggressiveness denoted by multiple relapses and morphogenetic tests particularizes the case and improves the literature by bringing new information about this rare neoplasm of the central nervous system.

1 January 2015
Verified
Journal Article
Closed access
DTDoina Ecaterina Tofolean
Doina Ecaterina Tofolean
LMLaura Mazilu
Laura Mazilu
FSFlorica Stăniceanu
Florica Stăniceanu
Liliana SeicaruLiliana Seicaru
Liliana Seicaru
ASAndra-Iulia Suceveanu
Andra-Iulia Suceveanu
FVFelix Voinea
Felix Voinea

1 February 2021 in Ars Medica Tomitana
Verified
Journal Article
Open access
PDF file
Liliana SeicaruLiliana Seicaru
Liliana Seicaru
MEMunteanu-David Ramona Elena
Munteanu-David Ramona Elena
DSDeacu Sorin
Deacu Sorin
Lichen sclerosus (LS) is a chronic mucocutaneous sclerosis most commonly affecting the genital area, although extragenital localizations have also been described1, with unknown pathogenesis. Our study aims to analyze the morphopathological aspects of LS through the prism of polarized microscopy and with the help of histochemical information provided by special Van Gieson stain for elastic tissue and Picro-Sirius Red special stain. Picro-Sirius Red staining allows observation of the type of collagen synthesized in pathological conditions such as LS, as well as the appearance of mature hyalinization through loss of elastic tissue, and also the disappearing of piloerectile muscles.

11 October 2022 in Fetal and Pediatric Pathology
Verified
Journal Article
Closed access
MEManuela Enciu
Manuela Enciu
GBGabriela Izabela Bălţătescu
Gabriela Izabela Bălţătescu
OCOana Cojocaru
Oana Cojocaru
IBIonut Burlacu
Ionut Burlacu
VCViorel Constantin Cristurean
Viorel Constantin Cristurean
ANAntonela-Anca Nicolau
Antonela-Anca Nicolau
Background: Teratomas can occur in the umbilical cord, and may or may not be associated with other congenital abnormalities. Case report: This 35-year-old primigravida gave birth 37–38 weeks to a 3290-g normal female. The umbilical cord, at 10 cm from the abdominal insertion, had an 8 cm mature teratoma. Work-up revealed no other abnormalities. Discussion: Mature teratomas may occur in the umbilical cord, and may or may not have additional clinical sequalae.
1